U.S. pharma giant copyright scrapped two experimental weight loss pills final calendar year—a when-each day capsule, lotiglipron, on account of elevated liver enzymes as well as a twice-every day capsule, danuglipron, because of solid Uncomfortable side effects—but CEO Albert Bourla